ASP3082 + carboplatin + pemetrexed + pembrolizumab

ASP3082 + carboplatin + pemetrexed + pembrolizumab is an experimental combination regimen for the treatment of advanced or metastatic solid tumors with KRAS G12D mutation. - **ASP3082** is a novel, first-in-class, small-molecule proteolysis-targeting chimera (PROTAC) degrader that selectively binds and degrades the KRAS G12D-mutated protein by recruiting E3 ubiquitin ligase complexes, leading to proteasomal degradation of mutant KRAS[2][7]. ASP3082 is administered intravenously and is under early-phase clinical investigation to establish safety, tolerability, and effectiveness in humans[2][5][7]. - **Carboplatin** is a platinum-based chemotherapeutic agent that crosslinks DNA and interferes with DNA repair and replication, leading to cell death. - **Pemetrexed** is an antifolate antineoplastic agent that inhibits several enzymes involved in the folate pathway, thus blocking DNA synthesis in rapidly proliferating cells. - **Pembrolizumab** is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to restore and enhance anti-tumor immune responses. This combination is being evaluated in clinical trial settings in patients with advanced solid tumors harboring the KRAS G12D mutation and is not approved for any indication at this time[5].